Financial Performance - In the first half of 2025, Shengnuo Bio reported operating revenue of 338 million yuan, a year-on-year increase of 69.69% [1][2] - The net profit attributable to shareholders was approximately 89.9 million yuan, reflecting a significant year-on-year growth of 308.29% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was about 89.5 million yuan, marking a 367.92% increase compared to the previous year [1][2] Key Financial Metrics - The net cash flow from operating activities for the reporting period was approximately 81.7 million yuan, up from 26.1 million yuan in the same period last year [2] - The total assets of the company at the end of the reporting period were approximately 1.76 billion yuan, compared to 1.65 billion yuan at the end of the previous year [2] - The net assets attributable to shareholders were approximately 993 million yuan, an increase from 918 million yuan at the end of the previous year [2] Business Drivers - The increase in net profit was primarily driven by a significant rise in overseas sales of the raw materials Semaglutide and Teriparatide [2] - A delay in the payment of the second phase of cooperation funds for the outsourced project of injectable octreotide microspheres led to a reduction in R&D expenses compared to the previous year [2] - The market business expenses decreased due to price adjustments in the collection of injectable octreotide in May 2024 [2] - The company received a refund of 4 million yuan from the Meishan Finance Bureau for land guarantee deposits, which contributed to the reversal of credit impairment losses [2] Management Profile - Yu Xiaohai, the Deputy General Manager and Secretary of the Board, has been with the company since January 2022 and has a background in finance and investor relations [3] - His compensation over the years has been relatively lower than the industry average, with figures of 55.71 thousand yuan in 2022, 52.28 thousand yuan in 2023, and 54.57 thousand yuan projected for 2024 [4]

Core Viewpoint - Shengnuo Bio (688117.SH) reported significant growth in its 2025 semi-annual results, with revenue reaching 338 million yuan, a year-on-year increase of 69.69%, and net profit attributable to shareholders soaring by 308.29% to 88.96 million yuan [1] Financial Performance - The company achieved a revenue of 338 million yuan, reflecting a 69.69% increase compared to the previous year [1] - Net profit attributable to shareholders was 88.96 million yuan, marking a substantial year-on-year growth of 308.29% [1] - The non-recurring net profit was 89.48 million yuan, which represents a remarkable increase of 367.92% year-on-year [1] - Basic earnings per share stood at 0.57 yuan [1] Key Drivers of Growth - The significant increase in net profit was primarily driven by: 1. A substantial rise in overseas sales of raw materials, Semaglutide and Teriparatide, contributing to profit growth [1] 2. A delay in the outsourced project for injectable Acetate Octreotide with Meihua Dingchang, resulting in reduced R&D expenses compared to the previous year [1] 3. A price adjustment in the collection of injectable Octreotide in May 2024, leading to decreased market business expenses [1] 4. A refund of land deposit from the Meishan Finance Bureau in March 2025, which reversed credit impairment losses by 4 million yuan [1]

Core Viewpoint - Shengnuo Biotech (688117.SH) has reported significant growth in its half-year performance for 2025, with net profit expected to increase by 253.54% to 332.1% year-on-year, driven by strong performance in its peptide raw material business [1][3]. Financial Performance - The company anticipates a net profit of between 77.03 million yuan and 94.14 million yuan for the first half of 2025, with a year-on-year increase of 253.54% to 332.1% [1][3]. - The expected non-deductible net profit is projected to be between 77.35 million yuan and 94.53 million yuan, reflecting a year-on-year increase of 304.49% to 394.38% [1][3]. - In 2024, Shengnuo Biotech reported revenue of 456 million yuan, a year-on-year growth of 4.84%, while net profit decreased by 28.88% to 50.02 million yuan due to increased R&D investment and other factors [2]. Business Operations - Shengnuo Biotech is actively expanding its production capacity to meet market demand, with projects such as the "Annual Production of 395 kg Peptide Raw Material Production Line" and the expansion of raw material workshops [3]. - The company has successfully launched its 106 workshop and is in the equipment validation phase for workshops 107 and 108 [3]. Market Expansion - The global peptide CDMO market is projected to reach $11.8 billion by 2030, with the domestic market expected to reach 18.5 billion yuan, indicating a higher CAGR than the global market [4]. - Shengnuo Biotech's overseas revenue reached 148 million yuan in 2024, a significant increase of 73.93%, while domestic revenue decreased by 12.51% to 303 million yuan [4]. - The proportion of overseas revenue has increased to 32.52%, up 12.92 percentage points from 2023, reflecting the company's focus on expanding its international sales channels [4]. R&D and Product Development - The company is collaborating with external firms to develop various peptide products and has significantly increased its R&D investment, with expenses rising from 13.75 million yuan in 2021 to 49.17 million yuan in 2024 [5]. - Shengnuo Biotech provides CDMO services for over 40 peptide innovation drug projects, with two products approved for commercialization and two in the production application stage [5].